Pts with histologically or cytologically confirmed stage IIIB/IIIC or IV NSCLC without sensitizing EGFR/ALK/ROS1 mutations must had progressed during or after a PD-1/L1 inhibitor and a platinum-based chemotherapy;AK104 + anlotinib + docetaxel; N=33;. This evidence concerns the gene ALK and non-small cell lung carcinoma.